Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $266.48 and traded as low as $218.93. Genmab A/S shares last traded at $218.93, with a volume of 765 shares trading hands.
Genmab A/S Trading Up 3.5 %
The stock has a 50 day simple moving average of $253.05 and a 200-day simple moving average of $266.21. The firm has a market capitalization of $14.82 billion, a P/E ratio of 18.76 and a beta of 1.06.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.13 earnings per share (EPS) for the quarter. The company had revenue of $779.50 million during the quarter. Genmab A/S had a return on equity of 20.60% and a net margin of 29.06%.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
